MedTrace Logo

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

NCT00630110 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2011-08-16

No results posted yet for this study

Summary

This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues.

Conditions

Interventions

DRUG

docetaxel

docetaxel (75 mg/m2)

DRUG

NPI-2358 + docetaxel

NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)

Sponsors & Collaborators

  • Nereus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Matthew A Spear, MD · Chief Medical Officer, Nereus Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Chile
  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630110 on ClinicalTrials.gov